Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

NA

Total Enrollment

2500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-12

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Collection of Nasal Swabs, Throat Swabs and Saliva Samples from patients presenting at their designated care or testing facility displaying symptoms of either Influenza, Respiratory Syncytial Virus (RSV), SARS-CoV-2 or those who have been in recent contact with SARS-CoV-2 positive patients. Collected samples will aid the development, calibration and performance evaluation of the LumiraDx POC Test.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)

NCT05787444

SARS-CoV-2 Influenza A Influenza B +1 more

UNKNOWN

Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B

NCT02487173

Influenza A Influenza B

COMPLETED NA

Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

NCT06734741

COVID-19 Influenza A Influenza B

COMPLETED

Respiratory Virus Sampling and Repository

NCT05266222

Influenza COVID-19

RECRUITING

Study of VIR-2482 in Healthy Volunteers

NCT04033406

Influenza A

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

INFORM is a sample collection study targeting a population of patients attending their designated care or testing facility, suspected of having a respiratory illness typical of Influenza, RSV or COVID-19 and undergoing a Standard of Care (SOC) test on the day. Or those who have been in recent contact with SARS-CoV-2 positive patients. Participants may be of any age, there is no upper or lower age limit.

Depending on the facility's viability and agreed contracting, the following study samples will be collected per patient:

Adult Population: Two (2) Nasal, AND/OR Two (2) Throat Swabs AND/OR, One (1) Saliva Sample

Paediatric Population: Two (2) Nasal, OR Two (2) Throat Swabs AND/OR, One (1) Saliva Sample

Once required samples and data have been collected, participation is complete. No follow-up or subsequent patient involvement is required.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 RSV Infection Influenza Type A Influenza Type B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sample Collection - Symptomatic Patients

The patient will be completing or has completed a SOC Influenza A/B and/or COVID-19 and/or RSV test on the day of study

Group Type OTHER

Sample Collection

Intervention Type OTHER

Sample Collection - Adult Population:

* Two (2) Nasal AND/OR
* Two (2) Throat Swabs AND/OR
* One (1) Saliva Sample

Sample Collection - Paediatric Population:

* Two (2) Nasal OR
* Two (2) Throat Swabs AND/OR
* One (1) Saliva Sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sample Collection

Sample Collection - Adult Population:

* Two (2) Nasal AND/OR
* Two (2) Throat Swabs AND/OR
* One (1) Saliva Sample

Sample Collection - Paediatric Population:

* Two (2) Nasal OR
* Two (2) Throat Swabs AND/OR
* One (1) Saliva Sample

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Preliminary assessment of the patient by the Investigator/Designee should be suggestive of Influenza and/or COVID-19 and/or RSV at the time of the study visit. This may include referral to a testing facility.
* The patient will be completing or has completed a Standard of Care (SOC) Influenza A/B, COVID-19 and/or an RSV test on the day of study. This SOC sampling can be conducted prior or post the patient consenting to this study.
* Written Informed Consent must be obtained prior to study enrolment:

* A participant who is 16 years or older must be willing to give written informed consent and must agree to comply with study procedures.
* The Legal Guardian or Legal Authorised Representative of a participant who is under the age of 16 must give written informed consent and agree to comply with study procedures. Active written assent should be obtained from children of appropriate intellectual age (as determined by the consent taker in accordance with GCP).

Exclusion Criteria

* The patient underwent a nasal wash/aspirate as part of standard of care testing during their current visit.
* The patient is undergoing treatment currently and/or within the past 14 days of the study visit with an inhaled influenza vaccine (FluMist®) or anti-viral medication, which may include but is not limited to Amantadine (Symmetrel®), Rimantadine (Flumadine®), Zanamivir (Relenza®), Oseltamivir (Tamiflu®), or Baloxavir Marboxil (Xofluza™).
* The patient is undergoing treatment currently or had undergone within the past 14 days of the study visit with RSV-related medication which may include but is not limited to Ribavirin (Virazole), RSV-IGIV (RespiGam) or palivizumab (Synagis).
* The patient is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, drug, or device including either treatment or therapy.
* The patient does not have the capacity to consent as determined by the Research Team.
* The patient is deemed to be unsuitable for research at the Research Team's discretion.

Eligible Sex

ALL

Accepts Healthy Volunteers

No